Seres Therapeutics (MCRB) Cut to “Sell” at BidaskClub

Share on StockTwits

BidaskClub cut shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a sell rating in a research report sent to investors on Thursday.

Other research analysts have also recently issued reports about the company. Cantor Fitzgerald reissued an overweight rating on shares of Seres Therapeutics in a report on Friday, November 23rd. Chardan Capital assumed coverage on Seres Therapeutics in a report on Monday, October 22nd. They set a buy rating and a $15.00 price objective for the company. ValuEngine raised Seres Therapeutics from a sell rating to a hold rating in a report on Tuesday, September 4th. Oppenheimer set a $16.00 price objective on Seres Therapeutics and gave the company a buy rating in a report on Friday, November 9th. Finally, Zacks Investment Research cut Seres Therapeutics from a buy rating to a hold rating in a report on Wednesday, November 14th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of $13.81.

Shares of MCRB stock opened at $6.39 on Thursday. Seres Therapeutics has a one year low of $5.64 and a one year high of $11.35. The company has a debt-to-equity ratio of 0.85, a quick ratio of 2.04 and a current ratio of 2.04.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.03. The company had revenue of $9.06 million during the quarter, compared to analysts’ expectations of $23.43 million. Seres Therapeutics had a negative return on equity of 1,584.66% and a negative net margin of 515.16%. On average, sell-side analysts anticipate that Seres Therapeutics will post -2.58 EPS for the current fiscal year.

In other Seres Therapeutics news, insider John G. Aunins sold 42,837 shares of Seres Therapeutics stock in a transaction on Monday, September 17th. The stock was sold at an average price of $7.64, for a total transaction of $327,274.68. Following the completion of the transaction, the insider now directly owns 146,648 shares of the company’s stock, valued at $1,120,390.72. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John G. Aunins sold 14,279 shares of Seres Therapeutics stock in a transaction on Monday, October 15th. The shares were sold at an average price of $5.94, for a total value of $84,817.26. Following the transaction, the insider now directly owns 103,811 shares of the company’s stock, valued at $616,637.34. The disclosure for this sale can be found here. 37.10% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Seres Therapeutics in the second quarter valued at about $117,000. Paloma Partners Management Co bought a new position in shares of Seres Therapeutics in the third quarter valued at about $147,000. Jefferies Group LLC raised its holdings in shares of Seres Therapeutics by 75.5% in the third quarter. Jefferies Group LLC now owns 21,424 shares of the biotechnology company’s stock valued at $163,000 after buying an additional 9,215 shares during the last quarter. Citadel Advisors LLC raised its holdings in shares of Seres Therapeutics by 48.0% in the third quarter. Citadel Advisors LLC now owns 31,400 shares of the biotechnology company’s stock valued at $239,000 after buying an additional 10,183 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Seres Therapeutics by 175.0% in the second quarter. Bank of America Corp DE now owns 36,489 shares of the biotechnology company’s stock valued at $314,000 after buying an additional 23,222 shares during the last quarter. 78.35% of the stock is owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

Further Reading: Stock Symbols Definition, Examples, Lookup

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply